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 Research in context  
 
Evidence before this study 
Using PubMed and Google Scholar the authors reviewed prior work on longitudinal 
neuroimaging markers of Alzheimer pathology with a focus on autosomal dominant 
Alzheimer disease (ADAD). We searched for all articles prior to October 31
st
, 2017 with 
no language restrictions for the keywords Alzheimer’s, Alzheimer, longitudinal, positron 
emission tomography, PET, MRI, atrophy, FDG, hypometabolism, familial, and 
autosomal. Theories proposed initially in 2010 by Jack and colleagues and revised in 
2013 posited temporal trajectories of Alzheimer biomarkers relative to each other and 
clinical decline. Work by Bateman and colleagues in 2012, Benzinger and colleagues in 
2013, and Fleisher and colleagues in 2015 depict such temporal ordering of biomarkers in 
ADAD populations derived from cross-sectional analyses. There was also a small subset 
of longitudinal ADAD studies, but these had one or more limitation such as small 
populations (n<50), examination of only one biomarker, not accounting for regional 
differences or correlations in the brain, or had a short duration of longitudinal followup. 
 
Added value of this study 
Our study presents the first known work examining both the longitudinal temporal 
trajectories and spatial patterns of Alzheimer pathology in ADAD cohorts using 
neuroimaging. This work also presents the largest known cohort to date of ADAD 
individuals studied longitudinally with multiple neuroimaging biomarkers. Longitudinal 
analyses can provide a more accurate and powerful way to model the temporal 
emergence of pathology in ADAD. We find that mutation carriers first display Aβ 
accumulation, followed by hypometabolism, and finally structural atrophy; this is 
consistent with theoretical models and cross-sectional estimates from ADAD. Most 
importantly we consider such temporal relationships not in one singular summary 
measure, but characterize these trajectories throughout the brain. We found that the 
accrual of pathology varied throughout the brain and by modality in terms of the time of 
initial emergence and the rates of longitudinal change. These findings suggest region 
specific vulnerabilities to β-amyloidosis, metabolic decline, and atrophy that change over 
the course of the disease.   
 
Implications of all the available evidence 
Our results build upon existing evidence characterizing biomarkers in clinical and 
preclinical Alzheimer disease. Our findings suggest that imaging biomarkers follow a 
sequential pattern, with β-amyloidosis, hypometabolism, and structural atrophy emerging 
more than twenty, fifteen, and ten years respectively before the expected onset of 
dementia. Although there is a general hierarchical pattern, there was considerable 
regional heterogeneity. Most commonly, regions demonstrated an increase in β-
amyloidosis and structural atrophy, but there was not evidence of metabolic declines. 
Further, rather than being homogenous, the same biomarker often demonstrates different 
longitudinal trajectories across brain regions. Characterizing the temporal and regional 
dynamics provides insight into disease pathophysiology. This information is critical to 
decide how to best use neuroimaging biomarkers in clinical trials for subject selection as 
well as outcomes measures.  
 Abstract  
Background 
Models of Alzheimer disease propose a sequence of amyloid-β (Aβ) accumulation, 
hypometabolism, and structural declines that precede the onset of clinical dementia. 
These pathological features evolve both temporally and spatially in the brain. This study 
aimed to characterize where in the brain and when in the course of the disease 
neuroimaging biomarkers become abnormal.  
 
Methods 
We analyzed data from mutation non-carriers, asymptomatic carriers, and symptomatic 
carriers collected between January 1
st
 2009 and December 31
st
 2015 from families 
carrying PSEN1, PSEN2, or APP mutations enrolled in the Dominantly Inherited 
Alzheimer’s Network. We analyzed [11C]Pittsburgh Compound B positron emission 
tomography (PiB PET), [
18
F]Fluorodeoxyglucose (FDG PET), and structural magnetic 
resonance imaging (MRI) data using regions of interest to assess change throughout the 
brain. We estimated rates of biomarker change as a function of estimated years from 
symptom onset at baseline using linear mixed-effects models and determined the earliest 
point at which biomarker trajectories differed between mutation carriers and non-carriers.  
 
Findings 
PiB PET was available for 346 individuals, with 162 having longitudinal imaging; FDG 
PET was available for 352 (175 longitudinal); and MRI data was available for 377 (201 
longitudinal). We found a sequence to pathological changes, with rates of Aβ deposition 
in mutation carriers being significantly different from non-carriers first (on average 
across significant regions at -18·9 (sd 3·3) years before expected onset), followed by 
hypometabolism (-14·1 years, sd 5·1) and lastly structural declines (-4·7 years, sd 4·2). 
This biomarker ordering was preserved in most, but not all, regions. The temporal 
emergence within a biomarker varied across the brain, with the precuneus being the first 
cortical region in each modality to show divergence between groups.  
 
Interpretation 
Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and 
cortical thinning which preceded the expected onset of dementia. We found that the 
accrual of these pathologies varied throughout the brain, suggesting differential regional 
and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy. This 
provides insight into the temporal and spatial development of pathological change in 
Alzheimer disease. Understanding where and when pathology accrues in the brain is key 
for using biomarkers in a clinical setting as well as designing and evaluating clinical 
trials. 
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  1 
Introduction  
Alzheimer disease (AD) presents as a progressive loss of cognitive function, leading to 
severe impairment and loss of independence. AD’s long preclinical phase has bolstered 
efforts to identify in vivo biomarkers to aid disease diagnosis and prognosis
1
. Models of 
AD pathophysiology theorize a temporal sequence where disruptions in amyloid-β (Aβ) 
production and/or clearance initiate a biological cascade that leads to Aβ plaque 
formation that spreads throughout the cortex followed by tauopathy, neuronal 
dysfunction and death, and ultimately dementia
2,3
.  
 
Positron emission tomography (PET) and magnetic resonance imaging (MRI) can assess 
both the amount and location of Aβ plaques, tauopathy (neurofibrillary tangles, neuritic 
plaques, and neuropil), altered glucose metabolism, and structural decline. The temporal 
sequence of these biomarkers provides information about the pathogenesis of AD. 
Determining the ordering of changes in sporadic AD is problematic, as it is difficult to 
predict an individual’s relative position in the disease. Autosomal dominant AD (ADAD) 
is well suited to study biomarker trajectories due to the virtually complete penetrance of 
the mutations and consistency of symptom onset within families
4,5
. The conserved onset 
age within families and mutation types allows individuals to be staged relative to their 
expected onset of symptoms.  
 
ADAD work has revealed a temporal ordering of biomarkers consistent with theoretical 
models,
6–8
 and indications that pathology progressively appears in new regions of the 
brain as the disease worsens
7
. This has primarily relied on cross-sectional analyses, with 
limited analyses of modest longitudinal cohorts
7,9–16
. Longitudinal analyses can provide a 
better estimate of the true pathological trajectories.
17,18
 This is critical as interventional 
trials such as the Dominantly Inherited Alzheimer Network (DIAN) trials unit,
19
, the 
Alzheimer’s Prevention Initiative (API),20 and the Anti-Amyloid Treatment in 
Asymptomatic Alzheimer’s Study (A4)21 will all evaluate alterations in longitudinal 
biomarker trajectories.  
 
The DIAN observational study (DIAN)
4
 has established a large cohort of ADAD families 
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with longitudinal Aβ, metabolic, and structural neuroimaging assessments. Our current 
work compares rates of biomarker change in a large population of mutation carriers (MC) 
and non-carriers (NC) throughout the entire brain. In this way we can visualize when 
pathology biomarkers first emerge and how they spread throughout the course of the 
disease.  
 
Methods 
Participants  
Individuals from families known to have mutations in the presenilin 1 (PSEN1), 
presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes were recruited from 14 
performance sites participating in the DIAN observational study (http://www.dian-
info.org). Participants were recruited from DIAN sites in the United States, Great Britain, 
Germany, and Australia between January 1
st
 2009 and December 31
st
 2015. All 
participants with genetic, clinical, and neuroimaging data that passed quality control from 
the tenth semiannual data freeze were included in the analyses. The institutional review 
board at Washington University in St. Louis provided supervisory review and human 
studies approval. Participants or their caregivers provided written informed consent in 
accordance with their local institutional review board. Clinical and imaging visits in 
DIAN are performed every three years for asymptomatic individuals until they are within 
three years of their parental age of dementia onset. Assessments become annual once an 
individual is within three years of parental age at onset or if an individual becomes 
symptomatic. Analyses excluded families with the Dutch and Flemish Mutation, as these 
APP mutations often present with predominant cerebral amyloid angiopathy and diffuse 
Aβ plaques (see supplemental material). The analyses included 346 individuals with Aβ 
PET data, 352 with PET metabolism data, and 377 with MRI.  
 
Clinical Assessment.  
Dementia status was assessed using the Clinical Dementia Rating (CDR)
22
. For each visit 
a participant’s estimated years from expected symptom onset (EYO) was calculated 
based upon the participant’s current age relative to either the family mutation specific 
expected age at dementia onset
5
or parental age at first progressive cognitive decline if 
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mutation age at onset was unknown. A “mutation specific” expected age of dementia 
onset is calculated by averaging the age of onset reported in the literature across 
individuals with the same specific mutation
5
. EYO is established identically for both 
carriers and non-carriers. The presence or absence of an ADAD mutation was determined 
using PCR-based amplification of the appropriate exon followed by Sanger sequencing
6
. 
Clinical evaluators were blind to participant mutation status.  
 
MRI.  
MRI was performed using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
protocol
23
. Sites used a 3T scanner and were required to pass regular quality control 
assessments. T1-weighted images (1·1 x 1·1 x 1·2-mm voxels) were acquired for all 
subjects. The ADNI Imaging Core screened images for protocol compliance and artifacts. 
Volumetric segmentation and cortical surface reconstruction was performed using 
FreeSurfer 5·3
24,25
 which automatically defines subcortical and cortical regions of interest 
(ROIs). Segmentations were inspected by members of the DIAN Imaging Core and 
edited as needed. Subcortical volumes were corrected for intracranial volume using a 
regression approach. Cortical thickness and volume measures were averaged across 
hemispheres. The cortical and subcortical labels identified on the MRI were utilized for 
the regional processing of all PET data. For all analyses we examined 34 cortical ROIs 
and 7 subcortical ROIs. A full list of regions is available in supplemental material.   
 
PET.  
Aβ imaging was performed using a bolus injection of [11C]Pittsburgh Compound B (PiB). 
Acquisition consisted of a 70-minute scan starting at injection or a 30-minute scan 
beginning 40 minutes post-injection. Data in the common 40–70 minute time frame was 
converted to regional standardized uptake value ratios (SUVRs) relative to the cerebellar 
grey matter using FreeSurfer derived regions of interest
26
 (PET Unified Pipeline, 
https://github.com/ysu001/PUP). Metabolic imaging was performed with 
[
18
F]Fluorodeoxyglucose (FDG) with a 30-minute dynamic acquisition beginning 30 
minutes after injection. Data from the last 20 minutes of each FDG scan were converted 
to SUVRs relative to cerebellar grey. Both types of PET data were partial volume 
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corrected using a regional spread function technique
27,28
.  
 
As there were no a priori laterality predictions, data were averaged across hemispheres 
before being entered into statistical analyses. Differences in spatial resolution across PET 
scanners were accounted for by applying scanner specific spatial filters to achieve a 
common resolution (8 mm)
29
. The ADNI PET Core verified that PET images were 
acquired using the established protocol and substantially free of artifacts.  
 
Statistical Analyses 
We used multivariate linear mixed effects (LME) models to describe the evolution of 
Alzheimer disease biomarkers. LME models have many benefits including providing a 
flexible approach to deal with an unequal number of measurement points or intervals. 
While neuroimaging analyses traditionally use univariate models, the field has begun 
using multivariate models which account for correlations between regional or voxelwise 
measurements
30–32
. Multivariate LME models can increased statistical power and 
reliability compared to univariate methods
30,31
. We implemented a Bayesian multivariate 
LME model to directly compare longitudinal biomarker changes across brain regions. 
Cortical and subcortical measurements were analyzed separately for each modality (PiB, 
FDG, and volumetric), resulting in total of six independent models. 
 
The full Bayesian LME model is described in the supplemental material. Each region 
included fixed effects for mutation status, time from baseline, baseline EYO, and all 
possible two and three-way interactions. EYO was modeled as a restricted cubic spline 
with knots at the 0·10, 0·50, and 0·90 quantiles. We chose restricted cubic splines to 
model EYO as they represent a flexible approach for accounting for nonlinearities in the 
data without forcing any particular curve shape. Splines have also been used extensively 
in the literature to model longitudinal changes in Alzheimer disease biomarkers
33,34
. For 
every region we included random intercepts and slopes at the subject-level, as well as 
random intercepts for family affiliation. At the subject-level, covariance matrices were 
constructed so that intercepts and the slopes were allowed to correlate across all regions 
in a model. 
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To fit each model we used Stan (http://mc-stan.org/)
35,36
, an open source package for 
Hamilton Markov chain Monte Carlo analyses. A parameter, or combination of 
parameters, was considered statistically significant if the 99% equal-tailed credible 
intervals of the posterior distribution did not overlap zero. Analyses were run separately 
for each modality (MRI, PiB, and FDG). Within each modality one model simultaneously 
fit 34 cortical ROIs and a second model simultaneously fit 7 subcortical ROIs derived 
from FreeSurfer. Each regional comparison within a model is simply a different slice of 
the same multidimensional posterior distribution. The current analyses focus on the 
interaction between mutation status and the longitudinal rate of change. Including 
multiple regions within one model also allows for the direct comparison of rates of 
changes between regions (supplemental material). 
 
Role of the funding source  
The study sponsors had no role in the study design, data collection, data analysis, data 
interpretation, writing of the report, or the decision to submit the manuscript for 
publication. All coauthors had full access to the data in the study and the corresponding 
author had final responsibility for the decision to submit for publication. 
 
Results 
Population demographics are in Table 1. Subjects with longitudinal data had an average 
of 2·4 visits (sd 0·8) and 2·7 (sd 1·1) years of data. Figure 1 shows example LME model 
fits for one region. For the both the middle and right-hand panels the shaded areas 
represent 99% credible intervals around the model estimates. The credible intervals are 
drawn from the actual distributions of model fits derived by the Hamilton Markov Chain 
Monte Carlos analyses. Any point in the difference curves (right-hand panels) where the 
shaded area is not touching the zero axis is a point in the disease progression (as 
measured by EYO) where the biomarker rate of change is different between groups. The 
first EYO point that was significantly different between groups was considered the initial 
diverge between groups. Figures depicting the model results for every ROI are available 
in supplemental materials. To avoid inadvertently revealing participants’ mutation status 
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at the edges of our sample where there are only a few individuals, figures are displayed 
with baseline EYO -29 to +10. 
 
The rate of Aβ accumulation is statistically higher in MC relative to NC participants 
starting more than two decades (EYO -22·2) before the expected age of dementia onset 
(Figure 1). As glucose utilization represents a natural biological property it contains both 
maturational and disease-related trajectories. In both groups, the precuneus FDG 
trajectories were initially positive, became neutral, and then negative. This negative 
directional acceleration begins earlier and was larger in MCs, with the rate of change 
becoming significantly less than NC at EYO -18·8. Finally, precuneus cortical thinning 
significantly differs in MC relative to NC at EYO -13·0. Supplemental material contains 
results for every ROI. Overall, in regions with a significant effect relative to NC, rates of 
Aβ deposition were significantly higher in MC at an average EYO of -18·9 (sd 3·3), 
metabolism began declining at an average EYO of -14·1 (sd 5·1), and MRI structural 
measures declined at an average EYO -4·7 (sd 4·2).  
 
Figure 2 depicts EYOs when and whether the longitudinal rate of change first differs 
between MC and NC for each biomarker. The differences across regions and modalities 
reflect the temporal and spatial evolution of pathology over the course of the disease. 
Rates of biomarkers change in regions that are grey are never significantly different 
between groups. This information is presented in numeric form in Supplemental Tables 1 
and 2. While many regions follow trajectories similar to the precuneus, the emergence of 
pathology varied throughout the brain. Further, there were regional differences by 
modality, for example, relative to NC the superior temporal lobe did not demonstrate a 
metabolic loss, but had atrophy changes at -5·6 EYO. Figure 3 depicts rates of change in 
MC for three cortical and three subcortical regions that exemplify common patterns.  
 
For PiB PET, 32/34 cortical regions showed significantly greater longitudinal rates of 
accumulation in MC relative to NC. The first point of divergence between groups varied 
across regions (EYO -22·2 to -2·5), with the precuneus, posterior cingulate gyrus, and 
medial orbital frontal cortex regions showing the earliest changes (~EYO -21). Of the 32 
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regions with significant differences, all but the cuneus (-2·5) occurred prior to an EYO of 
-15. In the seven subcortical regions the accumbens (-22·2), putamen (-17·0), and 
caudate (-16·4) demonstrated greater PiB accumulation rates in MC while the amygdala, 
hippocampus, palladium, and thalamus did not differ. Significant differences in 
progressive hypometabolism in MC relative to NC were less pronounced, with 8/34 
cortical regions demonstrating significant interactions. The effects ranged from EYO -
18·8 to -2·8, with the earliest effects detected in the precuneus, banks of the superior 
temporal sulcus, and caudal middle frontal cortex (EYO ~-18). No subcortical regions 
showed significant differences in the rate of FDG change. For MRI 24/34 cortical and 4/7 
subcortical areas demonstrated increased rates of atrophy in MC relative to NC with 
effects appearing from EYO -13·0 to 2·3. The precuneus (-13·0), banks of the superior 
temporal sulcus (-11·5), and inferior parietal cortex (-10·6) demonstrated the earliest 
changes.  
 
We also observed regional differences in the rates of biomarker change within the MC 
group. In the precuneus there was a rapid increase in Aβ deposition; this rate peaked but 
remained positive even after the predicted onset of dementia (Figure 3 and Figure 4). 
This was the most common pattern across areas. In other regions (e.g. insula) initial 
accelerations in Aβ deposition were followed by decelerations, leading to a plateau of 
total Aβ levels. In a subset of regions (e.g. inferior temporal cortex) the estimated rate of 
Aβ accumulation accelerates throughout the disease. Once declining, glucose metabolism 
in the precuneus showed prominent, worsening rates of hypometabolism before the rates 
stabilized (~ EYO -5), while in inferior temporal cortex the rate of metabolic loss 
modestly increased initially before quickly plateauing (Figure 3B). Many regions had 
relatively small rates of metabolic decline in MC, even at later EYOs. In regions with 
structural decline the trajectories were fairly consistent, with the rate of atrophy 
accelerating as the disease progressed. However, the absolute rate of decline was often 
different between regions. Matrices directly comparing the regional rates of change for 
each biomarker at different EYOs (-25, -15, -5, and 5) can be found in supplemental 
material. Voxel-wise movies depict the rate of change and total biomarker levels in MC 
at every EYO and the creation of these movies is detailed in supplemental material. 
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Discussion 
AD is not static but possesses dynamism in terms of what pathological processes first 
appear, and how such pathology propagates throughout the brain. As dementia onset is 
predictable in ADAD, it provides an elegant model with which to examine pathological 
staging. Characterizing the spatial and temporal spread of pathology provides insight to 
the pathophysiology of the disease, informs how neuroimaging could aid optimal subject 
recruitment in clinical trials, and is critical to measure the efficacy of interventions on 
longitudinal biomarker measurements.  
 
The primary goal of the current analysis was to find the first biomarker time point in the 
course of the disease where carriers of ADAD mutations demonstrated different rates of 
pathological progression relative-to non-carrier family members. This time point can be 
interpreted as the moment where longitudinal change in that brain area due to AD can 
first be detected with in vivo neuroimaging. The primary questions using this approach 
focused on regional differences across the brain within a marker (e.g. precuneus vs. 
parietal Aβ PET) as well as comparing spatial differences between biomarkers (e.g. Aβ 
PET vs. FDG PET).  
 
Consistent with prior work we found that Aβ deposition was the first biomarker to 
demonstrate differences between mutation groups. MC had greater Aβ deposition more 
than 20 years before the expected age of symptom onset. Aβ increases were near 
ubiquitous, with most regions changing more than 14 years before the expected year of 
dementia. Measures of metabolism in ADAD represent overlapping maturational and 
disease changes. Both NC and MC cohorts had inverted U-shaped trajectories (Figure 1D 
& 1E), with the absolute levels of glucose metabolism initially modestly increasing with 
EYO, followed by a prolonged decrease. The key difference is that MC showed 
metabolic reductions earlier and to a greater degree than NC. While cross-sectional 
values still overlapped between groups early in the disease, longitudinal trajectories 
reveal divergence (supplementary material). The precuneus demonstrates the earliest 
metabolic decrease an EYO of -18·8, with significant regions on average becoming 
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abnormal at EYO -14·1. Reductions in grey matter were the last neuroimaging biomarker 
to manifest and occured over the majority of the brain. Again the precuneus is one of the 
earliest regions to change, with declines emerging a decade before estimated dementia 
onset, while overall declines were most prolific in the five years preceding expected 
dementia onset. The direct comparison of the rates of biomarker change between regions 
is presented in supplementary material.   
 
The relationships between the three biomarkers are complex. While all regions with 
metabolic decreases have abnormal Aβ accumulation, many regions with abnormal Aβ 
accumulation rates did not demonstrate elevated metabolic decline. Although FDG 
hypometabolism and structural decline are markers of degeneration, our results indicate 
they can be incongruent. In regions where they both occur, declines in glucose 
metabolism precede atrophy by ~5 to 10 years. However, there are regions that 
demonstrated β-amyloidosis and structural atrophy where significant metabolic decline 
was not detected (e.g. occipital and temporal regions). Portions of the medial temporal 
lobe (e.g. the hippocampus) did not manifest pathological change in Aβ or FDG, but had 
structural declines. Although there is generally a tripartite hierarchy such that β-
amyloidosis precedes metabolic decline that in turn precede atrophy, these relationships 
are highly heterogeneous across the cortex.  
 
Discordance between imaging biomarkers has been noted in sporadic AD 
37–44
. Due to the 
cross-sectional nature of the majority of the work, such spatial incongruences could be 
due to temporal lags in the emergence of pathologies.
42,44
 EYO, as a marker of disease 
time, is perfectly suited to detect such temporal evolutions. The current work does indeed 
clearly demonstrate that a temporal progression is present in some regions (e.g. PiB, 
FDG, and cortical thinning in the precuneus). However, despite the long disease window 
covered by the current study population, some region still only demonstrate a subset of 
pathologies. This suggests the incongruences are not simply a product of temporal lag, 
but can represent true heterogeneity. Other, unobserved, biomarkers such as those that 
measure tau pathology and inflammation, may help explain this heterogeneous 
relationship.  
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The current work presents the largest and most comprehensive analysis of neuroimaging 
data in ADAD to date. Still, the majority of longitudinal subjects had only a limited 
follow-up (average 2·4 visits); results at the edges of the EYO range where outliers have 
disproportional influence must be interpreted with care. There are also only modest 
numbers of subjects with PSEN2 and APP mutations. As the DIAN study gains more 
time points longitudinal estimates will be improved further and it may be possible to 
compare the three types of mutations. A greater number of individuals and time points 
will also increase the feasibility of modeling multiple modalities simultaneously across 
all brain regions as previously done using summary measures of pathology.
45
  
 
The temporal and spatial ordering of biomarkers must also be interpreted with caveats. 
No one individual has data across the entire disease window, and our results represent 
population rather than individual subject effects. Further, as seen in regional fits (Figure 1 
and supplemental material) some individuals differ from population trajectories. Thus, 
imaging data alone may not be sufficient to make individual-level disease stage 
predictions. Such predictions would require further work that accounts for individual 
differences due to factors such as genetic variability and lifestyle. The current work also 
utilizes partial volume corrected PET data,
27,28
 analyses without this step could have 
slightly different trajectories late in the disease. 
 
The temporal ordering of biomarker change must also be viewed as relative rather than 
absolute. Our models are fit using a particular definition of EYO. Supplemental models 
using a modified definition of EYO indicate a preserved relative ordering (e.g. precuneus 
Aβ > hypometabolism > structural decline) but slight differences in absolute timing (e.g. 
shifts from EYO -22·2 to -19·8). Further, our results reflect the first detectable changes 
with PET and MRI, which are constrained by the inherent sensitivities and signal to noise 
properties of the imaging techniques. The current analyses utilize the cerebellum as a 
reference region for PET. Results using the brainstem instead were essentially unchanged 
(Supplementary Tables 3 and 4). Finally, although ADAD can serve as a model for 
sporadic AD, direct comparisons must explore potential differences. 
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Our results reveal complex patterns of biomarker accumulation across the brain. 
Elevations in β-amyloidosis occur more than two decades before and continue to accrue 
even after the expected year of symptom onset. Neurodegeneration measured with both 
FDG and structural MRI begins while Aβ is still increasing and occurs closer in time, but 
still well before the onset of dementia. While global measures likely capture a large 
degree of intraindividual variability, our results indicate not just when, but where 
pathology emerges in the brain. Understanding such longitudinal change provides insight 
into the pathophysiological progression of AD and has implications for clinical trials.  
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Figure 1: Modeling longitudinal change in the precuneus for PiB (top), FDG (middle), 
and cortical thickness (bottom). The left-hand panels (A, D, & G) depict the model 
estimates of longitudinal biomarkers. The middle panels (B, E, & H) depict the estimated 
rate of change across the course of the disease for mutation carriers and non-carriers. 
Individual random effect slope estimates are plotted as colored dots. The right hand 
panels (C, F, and I) depict the difference in rate of biomarker change between mutation 
carriers and non-carriers across the course of the disease. For both the middle and right-
hand panels the shaded areas represent 99% credible intervals around the model 
estimates. Any point in this difference curves where the shaded area is not touching the 
zero axis is a point in the disease progression (as measured by EYO) where the biomarker 
accumulation rate is different between groups. Figures depicting the model results for 
every ROI are available in supplemental materials. To avoid inadvertently revealing 
mutation status figures are displayed with baseline EYO -29 to +10. 
 
Figure 2: Emergence of neuroimaging biomarkers. The color scale represents the first 
point in the disease relative to estimated age at onset (EYO) where rates of biomarker 
change in that cortical region are significantly different between mutation carriers and 
non-carriers (akin to the first point where credible interval are different from zero in 
Figure 1 right panels). There is a temporal evolution where increased Aβ deposition 
precedes hypometabolism that in turn is followed by cortical thinning. Information for all 
modalities and regions is presented in numeric form in Supplemental Tables 1 and 2. 
 
Figure 3: Trajectories of biomarker accumulation in mutation carriers for three cortical 
(top) and three subcortical regions (bottom) for PiB (left), FDG (middle), and structural 
MRI (right) that highlight different patterns of change seen in different brain regions. 
 
Figure 4: Depictions of model estimates of rate of change in PiB (top), FDG (middle), 
and cortical thickness (bottom) in mutation carriers at an EYO of -25, -15, -5, and +5.  
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Table 1: Study demographics at baseline.  
 
Demographics at Baseline    
 Non-Carriers Asymptomatic Carriers Symptomatic Carriers 
Number 148 141 88 
Females (%) 85 (57%) 78 (55%) 49 (56%) 
Age (years/sd) 39·5 (11·4) 34·6 (9·2) 45·7 (9·9) 
MMSE (mean/sd) 29·0 (2·7) 28·8 (2·7) 23·9 (10·2) 
CDR-SOB (mean/SD) 0·0 (0·2) 0·0 (0·1) 3·6 (3·5) 
EYO (years/sd) -8·9 (11·4) -13·7 (9·2) 0·5 (7·1) 
PSEN1/PSEN2/APP 122/17/9 
(82/11/6%) 
117/16/8 
(83/11/6%) 
76/6/6 
(86/7/7%) 
N with Follow up (%) 70 (47%) 73 (52%) 58 (66%) 
N of visits*(sd) 2·3 (0·8) 2·3 (0·8) 2·8 (1·2) 
Follow up in years* (sd) 3·0 (1·7) 3·0 (1·6) 2·0 (1·3) 
    
Summary of Imaging Data    
Data By Modality PIB FDG MRI 
1 visit 184 177 176 
2 visits 124 131 145 
3 visits 23 27 35 
4 visits 10 11 11 
5 visits 4 5 8 
6 visits 1 1 2 
Total Subjects 346 352 377 
    
*Summary values are only for those individuals with longitudinal data 
EYO - estimated years to dementia onset 
MMSE –Mini Mental State Examination 
CDR-SOB – Clinical Dementia Rating Sum of Boxes  
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 Research in context  
 
Evidence before this study 
Using PubMed and Google Scholar the authors reviewed prior work on longitudinal 
neuroimaging markers of Alzheimer pathology with a focus on autosomal dominant 
Alzheimer disease (ADAD). We searched for all articles prior to October 31
st
, 2017 with 
no language restrictions for the keywords Alzheimer’s, Alzheimer, longitudinal, positron 
emission tomography, PET, MRI, atrophy, FDG, hypometabolism, familial, and 
autosomal. Theories proposed initially in 2010 by Jack and colleagues and revised in 
2013 posited temporal trajectories of Alzheimer biomarkers relative to each other and 
clinical decline. Work by Bateman and colleagues in 2012, Benzinger and colleagues in 
2013, and Fleisher and colleagues in 2015 depict such temporal ordering of biomarkers in 
ADAD populations derived from cross-sectional analyses. There was also a small subset 
of longitudinal ADAD studies, but these had one or more limitation such as small 
populations (n<50), examination of only one biomarker, not accounting for regional 
differences or correlations in the brain, or had a short duration of longitudinal followup. 
 
Added value of this study 
Our study presents the first known work examining both the longitudinal temporal 
trajectories and spatial patterns of Alzheimer pathology in ADAD cohorts using 
neuroimaging. This work also presents the largest known cohort to date of ADAD 
individuals studied longitudinally with multiple neuroimaging biomarkers. Longitudinal 
analyses can provide a more accurate and powerful way to model the temporal 
emergence of pathology in ADAD. We find that mutation carriers first display Aβ 
accumulation, followed by hypometabolism, and finally structural atrophy; this is 
consistent with theoretical models and cross-sectional estimates from ADAD. Most 
importantly we consider such temporal relationships not in one singular summary 
measure, but characterize these trajectories throughout the brain. We found that the 
accrual of pathology varied throughout the brain and by modality in terms of the time of 
initial emergence and the rates of longitudinal change. These findings suggest region 
specific vulnerabilities to β-amyloidosis, metabolic decline, and atrophy that change over 
the course of the disease.   
 
Implications of all the available evidence 
Our results build upon existing evidence characterizing biomarkers in clinical and 
preclinical Alzheimer disease. Our findings suggest that imaging biomarkers follows a 
sequential pattern, with β-amyloidosis, hypometabolism, and structural atrophy emerging 
more than twenty, fifteen, and ten years respectively before the expected onset of 
dementia. Although there is a general hierarchical pattern, there was considerable 
regional heterogeneity. Most commonly, regions demonstrated an increase in β-
amyloidosis and structural atrophy, but there was not evidence of metabolic declines. 
Further, rather than being homogenous, the same biomarker often demonstrates different 
longitudinal trajectories across brain regions. Characterizing the temporal and regional 
dynamics provides insight into disease pathophysiology. This information is critical to 
decide how to best use neuroimaging biomarkers in clinical trials for subject selection as 
well as outcomes measures.  
 Abstract  
Background 
Models of Alzheimer disease propose a sequence of amyloid-β (Aβ) accumulation, 
hypometabolism, and structural declines that precede the onset of clinical dementia. 
These pathological features evolve both temporally and spatially in the brain. This study 
aimed to characterize where in the brain and when in the course of the disease 
neuroimaging biomarkers become abnormal.  
 
Methods 
We analyzed data collected from mutation non-carriers, asymptomatic carriers, and 
symptomatic carriers collected between January 1
st
 2009 and December 31
st
 2015 from 
families carrying PSEN1, PSEN2, or APP mutations enrolled in the Dominantly Inherited 
Alzheimer’s Network. We analyzed [11C]Pittsburgh Compound B positron emission 
tomography (PiB PET), [
18
F]Fluorodeoxyglucose (FDG PET), and structural magnetic 
resonance imaging (MRI) data using regions of interest to assess change throughout the 
brain. We estimated rates of biomarker change as a function of estimated years from 
symptom onset at baseline using linear mixed-effects models and determined the earliest 
point at which biomarker trajectories differed between mutation carriers and non-carriers.  
 
Findings 
PiB PET was available for 346 individuals, with 162 having longitudinal imaging; FDG 
PET was available for 352 (175 longitudinal); and MRI data was available for 377 (201 
longitudinal). We found a sequence to pathological changes, with rates of Aβ deposition 
in mutation carriers being significantly different from non-carriers occurring first (on 
average across significant regions at -18·9 (sd 3·3) years before expected onset), 
followed by hypometabolism (-14·1 years, sd 5·1) and lastly structural declines (-4·7 
years, sd 4·2). This biomarker ordering was preserved in most, but not all, regions. The 
temporal emergence within a biomarker varied across the brain, with the precuneus being 
the first cortical region in each modality to show divergence between groups.  
, although the ordering across biomarkers was preserved in most, but not all, regions.  
 
Interpretation 
Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and 
cortical thinning which preceded the expected onset of dementia. We found that the 
accrual of these pathologies varied throughout the brain, suggesting differential regional 
and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy. This 
provides insight into the temporal and spatial development of pathological change in 
Alzheimer disease. Understanding where and when pathology accrues in the brain is key 
for using biomarkers in a clinical setting as well as designing and evaluating clinical 
trials. 
 
Funding 
National Institutes of Health UFAG032438, UL1TR000448, P30NS098577, 
R01EB009352, and NS080675, the German Center for Neurodegenerative Diseases, and 
the Medical Research Council Dementias Platform UK (MR/L023784/1 and 
MR/009076/1). ClinicalTrials.gov number, NCT00869817  
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Introduction  
Alzheimer disease (AD) presents as a progressive loss of cognitive function, leading to 
severe impairment and loss of independence. AD’s long preclinical phase has bolstered 
efforts to identify in vivo biomarkers to aid disease diagnosis and prognosis
1
. Models of 
AD pathophysiology theorize a temporal sequence where disruptions in amyloid-β (Aβ) 
production and/or clearance initiate a biological cascade that leads to Aβ plaque 
formation that spreads throughout the cortex followed by tauopathy, neuronal 
dysfunction and death, and ultimately dementia
2,3
.  
 
Positron emission tomography (PET) and magnetic resonance imaging (MRI) can assess 
both the amount and location of Aβ plaques, tauopathy (neurofibrillary tangles, neuritic 
plaques, and neuropil), altered glucose metabolism, and structural decline. The temporal 
sequence of these biomarkers provides information about the pathogenesis of AD. 
Determining the ordering of changes in sporadic AD is problematic, as it is difficult to 
predict an individual’s relative position in the disease. Autosomal dominant AD (ADAD) 
is well suited to study biomarker trajectories due to the virtually complete penetrance of 
the mutations and consistency of symptom onset within families
4,5
. The conserved onset 
age within families and mutation types allows individuals to be staged relative to their 
expected onset of symptoms.  
 
Cross-sectional ADAD work on ADAD has revealed a temporal ordering of biomarkers 
that is consistent with theoretical models,
6–8
 and indications that pathology progressively 
appears in new regions of the brain as the disease worsens
7
. This has primarily relied on 
cross-sectional analyses, with limited analyses of modest longitudinal cohorts
7,9–16
. 
Longitudinal analyses can provide a better estimate of the true pathological 
trajectoriesLongitudinal analyses can better estimate temporal dynamics and typically 
have more power to detect significant differences than cross-sectional analyses.
17,18
, as 
within subject measures reduce between-subject variability caused by unmodeled 
individual differences. Longitudinal analyses can provide a better estimate of the true 
pathological trajectories occurring in the disease. This is critically important as 
interventional clinical trials in such as the Dominantly Inherited Alzheimer Network 
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(DIAN) trials unit,
19, the Alzheimer’s Prevention Initiative (API),20 and the Anti-
Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4)21 will all evaluate 
alterations in longitudinal biomarker trajectories over time. Further, it is critical to 
understand how such temporal trajectories varies across the brain, as some regions may 
be more suitable for studying the efficacy of treatment than others.   
 
The DIAN observational study (DIAN)
4
 has established a large cohort of ADAD 
individuals from families with ADAD who obtainwith longitudinal Aβ, metabolic, and 
structural neuroimaging assessments. Our current work compares rates of biomarker 
change in a large population of mutation carriers (MC) and non-carriers (NC) throughout 
the entire brain. Although these modalities are often represented with aggregate summary 
measures, there are distinct spatial appearances and regional evolutions of each 
pathology
7,22,23
. Studying spatial patterns of longitudinal change provides information 
about local vulnerabilities to pathology that are lost when using summary measures.  
 
Our current work compares rates of biomarker change in a large population of mutation 
carriers (MC) and non-carriers (NC). Using linear mixed effects models, we compare 
biomarker change not using one summary measure, but throughout the brain. In this way 
we can visualize when pathology biomarkers first emerge and how they spread 
throughout the course of the disease. Clarifying changes in spatial patterns of biomarker 
accumulation over time will advance our understanding of disease pathobiology and 
provide critical information for the design and interpretation of disease-modifying 
clinical trials using biomarkers to enrich enrollment or as endpoints.  
 
Methods 
Participants  
Individuals from families known to have mutations in the presenilin 1 (PSEN1), 
presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes were recruited from 14 
performance sites participating in the DIAN observational study (http://www.dian-
info.org). Participants were recruited from DIAN sites in the United States, Great Britain, 
Germany, and Australia between January 1
st
 2009 and December 31
st
 2015. All 
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participants with genetic, clinical, and neuroimaging data that passed quality control from 
the tenth semiannual data freeze were included in the analyses. The institutional review 
board at Washington University in St. Louis provided supervisory review and human 
studies approval. Participants or their caregivers provided written informed consent in 
accordance with their local institutional review board. Clinical and imaging visits in 
DIAN were are performed every three years for asymptomatic individuals until they are 
within three years of their parental age of dementia onset. Assessments become annual 
once an individual is within three years of parental age at onset or if an individual 
becomes symptomatic. Analyses excluded families with the Dutch and Flemish Mutation, 
as these APP mutations often present with predominant cerebral amyloid angiopathy and 
diffuse Aβ plaques (see supplemental material). The analyses included 346 individuals 
with Aβ PET data, 352 with PET metabolism data, and 377 with MRI;. See Table 1 for 
baseline demographics. 
 
Clinical Assessment.  
Dementia status was assessed using the Clinical Dementia Rating (CDR)
22
. For each visit 
a participant’s estimated years from expected symptom onset (EYO) was calculated 
based upon the participant’s current age relative to either the family mutation specific 
expected age at dementia onset
5
, or parental age at first progressive cognitive decline if 
mutation age at onset was unknown. A “mutation specific” expected age of dementia 
onset is calculated by averaging the age of onset reported in the literature across 
individuals with the same specific mutation
5
. EYO is established identically for both 
carriers and non-carriers. The presence or absence of an ADAD mutation was determined 
using PCR-based amplification of the appropriate exon followed by Sanger sequencing
6
. 
Clinical evaluators were blind to participant mutation status.  
 
MRI.  
MRI was performed using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
protocol
23
. Sites used a 3T scanner and were required to pass regular quality control 
assessments. T1-weighted images (1·1 x 1·1 x 1·2-mm voxels) were acquired for all 
subjects. The ADNI Imaging Core screened images for protocol compliance and artifacts. 
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Volumetric segmentation and cortical surface reconstruction was performed using 
FreeSurfer 5·3
24,25
 which automatically defines subcortical and cortical regions of interest 
(ROIs). Segmentations were inspected by members of the DIAN Imaging Core and 
edited as needed. Subcortical volumes were corrected for intracranial volume using a 
regression approach. Cortical thickness and volume measures were averaged across 
hemispheres. The cortical and subcortical labels identified on the MRI were utilized for 
the regional processing of all PET data. For all analyses we examined 34 cortical ROIs 
and 7 subcortical ROIs. A full list of regions is available in supplemental material.   
 
PET.  
Aβ imaging was performed using a bolus injection of [11C]Pittsburgh Compound B (PiB). 
Acquisition consisted of a 70-minute scan starting at injection or a 30-minute scan 
beginning 40 minutes post-injection. Data in the common 40–70 minute time frame was 
converted to regional standardized uptake value ratios (SUVRs) relative to the cerebellar 
grey matter using FreeSurfer derived regions of interest
26
 (PET Unified Pipeline, 
https://github.com/ysu001/PUP). Metabolic imaging was performed with 
[
18
F]Fluorodeoxyglucose (FDG) with a 30-minute dynamic acquisition beginning 30 
minutes after injection. Data from the last 20 minutes of each FDG scan were converted 
to SUVRs relative to cerebellar grey. Both types of PET data were partial volume 
corrected using a regional spread function technique
27,28
.  
 
As there were no a priori laterality predictions, data were averaged across hemispheres 
before being entered into statistical analyses. Differences in spatial resolution across PET 
scanners were accounted for by applying scanner specific spatial filters to achieve a 
common resolution (8 mm)
29
. The ADNI PET Core verified that PET images were 
acquired using the established protocol and substantially free of artifacts.  
 
Statistical Analyses 
We used multivariate linear mixed effects (LME) models in order to describe the 
evolution of Alzheimer disease biomarkers. LME models have many benefits in 
longitudinal settings, including providing a flexible approach to deal with an unequal 
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number of measurement points or intervals. While neuroimaging analyses traditionally 
use univariate models, the field has begun using multivariate models which account for 
correlations between regional or voxelwise measurements
30–32
. Multivariate LME models 
can increased statistical power and reliability compared to univariate methods
30,31
. We 
implemented a Bayesian multivariate LME model to directly compare longitudinal 
biomarker changes across brain regions. Cortical and subcortical measurements were 
analyzed separately for each modality (PiB, FDG, and volumetric), resulting in total of 
six independent models. 
 
The full Bayesian LME model is described in detail in the supplemental material. Each 
region included fixed effects for mutation status, time from baseline, baseline EYO, and 
all possible two and three-way interactions. EYO was modeled as a restricted cubic spline 
with knots at the 0·10, 0·50, and 0·90 quantiles. We chose restricted cubic splines to 
model EYO as they represent a flexible approach for accounting for nonlinearities in the 
data without forcing any particular curve shape. Splines have also been used extensively 
in the literature to model longitudinal changes in Alzheimer disease biomarkers
33,34
. For 
every region we included random intercepts and slopes at the subject-level, as well as 
random intercepts for family affiliation. At the subject-level, covariance matrices were 
constructed so that intercepts and the slopes were allowed to correlate across all regions 
in a model. 
 
To fit each model we used Stan (http://mc-stan.org/)
35,36
, an open source package for 
Hamilton Markov chain Monte Carlo analyses. A parameter, or combination of 
parameters, was considered statistically significant if the 99% equal-tailed credible 
intervals of the posterior distribution did not overlap zero. Analyses were run separately 
for each modality (MRI, PiB, and FDG). Within each modality one model simultaneously 
fit 34 cortical ROIs and a second model simultaneously fit 7 subcortical ROIs derived 
from FreeSurfer. Each regional comparison within a model is simply a different slice of 
the same multidimensional posterior distribution. The current analyses focus on the 
interaction between mutation status and the longitudinal rate of change. Including 
multiple regions within one model also allows for the direct comparison of rates of 
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changes between regions (supplemental material). 
 
Role of the funding source  
The study sponsors had no role in the study design, data collection, data analysis, data 
interpretation, writing of the report, or the decision to submit the manuscript for 
publication. All coauthors had full access to the data in the study and the corresponding 
author had final responsibility for the decision to submit for publication. 
An example of one region is shown in Figure 1. For the both the middle and right-hand 
panels the shaded areas represent 99% credible intervals around the model estimates. The 
credible intervals are drawn from the actual distributions of model fits derived by the 
Hamilton Markov Chain Monte Carlos analyses. Any point in the difference curves 
(right-hand panels) where the shaded area is not touching the zero axis is a point in the 
disease progression (as measured by EYO) where the biomarker rate of change is 
different between groups. The first EYO point that was significantly different between 
groups was considered the initial diverge between groups. Figures depicting the model 
results for every ROI are available in supplemental materials. To avoid inadvertently 
revealing mutation status figures are displayed with baseline EYO -29 to +10. 
 
 
Results 
Population demographics are in Table 1. Subjects with longitudinal data had an average 
of 2·4 visits (sd 0·8) and 2·7 (sd 1·1) years of data. Figure 1 shows example LME model 
fits for one region. An example of one region is shown in Figure 1. For the both the 
middle and right-hand panels the shaded areas represent 99% credible intervals around 
the model estimates. The credible intervals are drawn from the actual distributions of 
model fits derived by the Hamilton Markov Chain Monte Carlos analyses. Any point in 
the difference curves (right-hand panels) where the shaded area is not touching the zero 
axis is a point in the disease progression (as measured by EYO) where the biomarker rate 
of change is different between groups. The first EYO point that was significantly 
different between groups was considered the initial diverge between groups. Figures 
depicting the model results for every ROI are available in supplemental materials. To 
Formatted: Font: Bold
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avoid inadvertently revealing mutationparticipants’ mutation status figuresat the edges of 
our sample where there are only a few individuals, figures are displayed with baseline 
EYO -29 to +10. 
 
As an example of one region Figure 1 shows the model fits for the precuneus stratified by 
mutation status. The rate of Aβ accumulation is statistically higher in MC relative to NC 
participants starting more than two decades (EYO -22·2) before the expected age of 
dementia onset (Figure 1). As glucose utilization represents a natural biological property 
it contains both maturational and disease-related trajectories. In both groups, the 
precuneus FDG trajectories were initially positive, became neutral, and then negative. 
This negative directional acceleration begins earlier and was larger in MCs, with the rate 
of change becoming significantly less than NC at EYO -18·8. Finally, precuneus cortical 
thinning  significantly differs in MC relative to NC at EYO -13·0. Supplemental material 
contains results for every ROI. Overall, in regions with a significant effect relative to NC, 
rates of Aβ deposition were significantly higher in MC at an average EYO of -18·9 (sd 
3·3), metabolism began declining at an average EYO of -14·1 (sd 5·1), and MRI 
structural measures declined at an average EYO -4·7 (sd 4·2).  
 
Figure 2 depicts EYOs when and whether the longitudinal rate of change first differs 
between MC and NC for each biomarker. The differences across regions and modalities 
reflect the temporal and spatial evolution of pathology over the course of the disease. 
Rates of biomarkers change in regions that are grey are never significantly different 
between groups. This information is presented in numeric form in Supplemental Tables 1 
and 2. While many regions follow trajectories similar to the precuneus, the emergence of 
pathology varied throughout the brain. Further, there were regional differences by 
modality, for example, relative to NC the superior temporal lobe did not demonstrate a 
metabolic loss, but had atrophy changes at -5·6 EYO. Figure 3 depicts rates of change in 
MC for three cortical and three subcortical regions that exemplify common patterns seen 
across regions.  
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For PiB PET, 32/34 cortical regions showed significantly greater longitudinal rates of 
accumulation in MC relative to NC. The first point of divergence between groups varied 
across regions (EYO -22·2 to -2·5), with the precuneus, posterior cingulate gyrus, and 
medial orbital frontal cortex regions showing the earliest changes (~EYO -21). Of the 32 
regions with significant differences, all but the cuneus (-2·5) occurred prior to an EYO of 
-15. In the seven subcortical regions the accumbens (-22·2), putamen (-17·0), and 
caudate (-16·4) demonstrated greater PiB accumulation rates in MC while the amygdala, 
hippocampus, palladium, and thalamus did not differ. Significant differences in 
progressive hypometabolism in MC relative to NC were less pronounced, with 8/34 
cortical regions demonstrating significant interactions. The effects ranged from EYO -
18·8 to -2·8, with the earliest effects detected in the precuneus, banks of the superior 
temporal sulcus, and caudal middle frontal cortex (EYO ~-18). No subcortical regions 
showed significant differences in the rate of FDG change. For MRI 24/34 cortical and 4/7 
subcortical areas demonstrated increased rates of atrophy in MC relative to NC with 
effects appearing from EYO -13·0 to 2·3. The precuneus (-13·0), banks of the superior 
temporal sulcus (-11·5), and inferior parietal cortex (-10·6) demonstrated the earliest 
changes.  
 
We also observed regional differences in the rates of biomarker change within the MC 
group. In the precuneus there was a rapid increase in Aβ deposition; this rate peaked but 
remained positive even after the predicted onset of dementia (Figure 3 and Figure 4). 
This was the most common pattern across areas. In other regions (e.g. insula) initial 
accelerations in Aβ deposition were followed by decelerations, leading to a plateau of 
total Aβ levels. In a subset of regions (e.g. inferior temporal cortex) the estimated rate of 
Aβ accumulation accelerates throughout the disease. Once it began to declinedeclining, 
glucose metabolism in the precuneus showed prominent, worsening rates of 
hypometabolism before the ratesa  constant rate of declinestabilized (~ EYO -5), while in 
inferior temporal cortex the rate of metabolic loss modestly increased initially before 
quickly plateauing later on in the disease (Figure 3B). Many regions had relatively small 
rates of metabolic decline in MC, even at later EYOs. In regions with structural decline 
the trajectories were fairly consistent, with the rate of atrophy accelerating as the disease 
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progressed. However, the absolute rate of decline was often different between regions. 
Matrices directly comparing the regional rates of change for each biomarker at different 
EYOs (-25, -15, -5, and 5) can be found in supplemental material. Voxel-wise movies 
depicting the rate of change and total biomarker levels in MC at every EYO and the 
creation of these movies are is detailed in supplemental material. 
 
Discussion 
AD is not a static disease but possesses dynamism in terms of what pathological 
processes first appear, and how such pathology propagates throughout the brain. As 
dementia onset is predictable in ADAD, it provides an elegant model with which to 
examine pathological staging. Characterizing the spatial and temporal spread of 
pathology provides insight to the pathophysiology of the disease, informs how 
neuroimaging could aid optimal subject recruitment in clinical trials, and is critical to 
measure the efficacy of interventions on longitudinal biomarker measurements.  
 
The primary goal of the current analysis was to find the first biomarker time point in the 
course of the disease where carriers of ADAD mutations demonstrated different rates of 
pathological progression relative-to non-carrier family members. This time point can be 
interpreted as the moment where the longitudinal change in that brain area due to AD can 
first be detected with in vivo neuroimaging. The primary questions using this approach 
focused on regional differences across the brain within a marker (e.g. precuneus vs. 
parietal Aβ PET) as well as comparing spatial differences between biomarkers (e.g. Aβ 
PET vs. FDG PET).  
 
Consistent with prior work in the field we found that Aβ deposition was the first 
biomarker to demonstrate differences between mutation groups. MC had greater Aβ 
deposition more than 20 years before the expected age of symptom onset. Aβ increases 
were near ubiquitous, with most regions changing more than 14 years before the expected 
year of dementia. Measures of metabolism in ADAD represent overlapping maturational 
and disease changes. Both NC and MC cohorts had inverted U-shaped trajectories 
(Figure 1D & 1E), with the absolute levels of glucose metabolism initially modestly 
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increasing with EYO, followed by a prolonged decrease. The key difference is that MC 
showed metabolic reductions earlier and to a greater degree than NC. While cross-
sectional values still overlapped between groups early in the disease, longitudinal 
trajectories reveal divergence (supplementary material). The precuneus demonstrates the 
earliest metabolic decrease in the brain at an EYO of -18·8, with significant regions on 
average becoming abnormal at EYO -14·1. Reductions in grey matter integrity were the 
last neuroimaging biomarker to manifest and occured over the majority of the brain. 
Again the precuneus is one of the earliest regions to change, with declines emerging a 
decade before estimated dementia onset, while overall declines were most prolific in the 
five years preceding the expected dementia onset. The direct comparison of the rates of 
biomarker change between regions is presented in supplementary material.   
 
The relationships between the three biomarkers are complex. While all regions that 
showedwith metabolic decreases have abnormal rates of Aβ accumulation, many regions 
with abnormal Aβ accumulation rates did not demonstrate elevated metabolic decline. 
Although FDG hypometabolism and structural decline are markers of degeneration, our 
results indicate they can be incongruent. In regions where they both occur, declines in 
glucose metabolism can precede atrophy by ~5 to 10 years. However, there are regions 
that demonstrated β-amyloidosis and structural atrophy where significant metabolic 
decline was not detected (e.g. occipital and temporal regions). Portions of the medial 
temporal lobe (e.g. the hippocampus) did not manifest pathological change in Aβ or 
FDG, but had structural declines. Although there is generally a tripartite hierarchy such 
that β-amyloidosis precedes metabolic decline that in turn precede atrophy, these 
relationships are highly heterogeneous across the cortex.  
 
Discordance between imaging biomarkers has been noted in studies of sporadic AD 
37–44
. 
Due to the cross-sectional nature of the majority of the work in the field, such spatial 
incongruences could be due to temporal lags in the emergence of pathologies. Work 
looking at cross-model relationships between baseline and longitudinal follow-up has 
shown such phenomena.
42,44
 EYO, as a marker of disease time, is perfectly suited to 
detect such temporal evolutions. The current work does indeed clearly demonstrate that a 
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temporal progression is present in some regions (e.g. PiB, FDG, and cortical thinning in 
the precuneus). However, despite the long disease window covered by the current study 
population, some region still only demonstrate a subset of pathologies. This suggests the 
incongruences are not simply a product of temporal lag, but can represent true 
pathological heterogeneity. Other, unobserved, biomarkers such as those that measure tau 
pathology and inflammation, may help explain this heterogeneous relationship.  
 
The current work presents the largest and most comprehensive analysis of neuroimaging 
data in ADAD to date. Still, the majority of longitudinal subjects had only a limited 
follow-up (average 2·4 visits); results at the edges of the EYO range where outliers have 
disproportional influence must be interpreted with care. and tThere are also only modest 
numbers of subjects with PSEN2 and APP mutations.  As the DIAN study gains more 
time points longitudinal estimates will be improved further and it may also be possible to 
examine patterns of change betweencompare the three types of mutations. A greater 
number of individuals and time points will also increase the feasibility of modeling 
multiple modalities simultaneously across all brain regions as previously done using 
summary measures of pathology.
45
  
 
The temporal and spatial ordering of biomarkers must also be interpreted with caveats. 
No one individual has data across the entire disease window, and our results represent 
population rather than individual subject effects. Further, as seen in regional fits (Figure 1 
and supplemental material) some individuals differ from population trajectories. Thus, 
imaging data alone may not be sufficient to make individual-level disease stage 
predictions. Such predictions would require further work that accounts for individual 
differences due to factors such as genetic variability and lifestyle. The current work also 
utilizes partial volume corrected PET data,
27,28
 analyses without this step could have 
slightly different trajectories late in the disease. 
 
The temporal ordering of biomarker change must also be viewed as relative rather than 
absolute. Our models are fit using a particular definition of EYO. Supplemental models 
using a slightly modified definition of EYO indicate a preserved relative ordering (e.g. 
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precuneus Aβ > hypometabolism > structural decline) but slight differences in absolute 
timing (e.g. precuneus PiB divergence shifts from EYO -22·2 to -19·8). Further, our 
results reflect the first detectable changes with PET and MRI, which are constrained by 
the inherent sensitivities and signal to noise properties of the imaging techniques. The 
current analyses utilize the cerebellum as a reference region for PET. Results using the 
brainstem instead were essentially unchanged (Supplementary Tables 3 and 4). Finally, 
although ADAD can serve as a model for sporadic AD, direct comparisons must explore 
potential differences. 
  
Our results reveal complex patterns of biomarker accumulation across the brain. 
Elevations in β-amyloidosis occur more than two decades before and continue to accrue 
even after the expected year of symptom onset. Neurodegeneration measured with both 
FDG and structural MRI begins while Aβ is still increasing and occurs closer in time, but 
still well before the onset of dementia. While global measures likely capture a large 
degree of intraindividual variability, our results indicate not just when, but where 
pathology emerges in the brain. Understanding such longitudinal change provides insight 
into the pathophysiological progression of AD and has important implications for clinical 
trials utilizing neuroimaging.  
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Figure 1: Modeling longitudinal change in the precuneus for PiB (top), FDG (middle), 
and cortical thickness (bottom). The left-hand panels (A, D, & G) depict the model 
estimates of longitudinal biomarkers. The middle panels (B, E, & H) depict the estimated 
rate of change across the course of the disease for mutation carriers and non-carriers. 
Individual random effect slope estimates are plotted as colored dots. The right hand 
panels (C, F, and I) depict the difference in rate of biomarker change between mutation 
carriers and non-carriers across the course of the disease. For both the middle and right-
hand panels the shaded areas represent 99% credible intervals around the model 
estimates. Any point in this difference curves where the shaded area is not touching the 
zero axis is a point in the disease progression (as measured by EYO) where the biomarker 
accumulation rate is different between groups. Figures depicting the model results for 
every ROI are available in supplemental materials. To avoid inadvertently revealing 
mutation status figures are displayed with baseline EYO -29 to +10. 
 
Figure 2: Emergence of neuroimaging biomarkers. The color scale represents the first 
point in the disease relative to estimated age at onset (EYO) where rates of biomarker 
change in that cortical region are significantly different between mutation carriers and 
non-carriers (akin to the first point where credible interval are different from zero in 
Figure 1 right panels). There is a temporal evolution where increased Aβ deposition 
precedes hypometabolism that in turn is followed by cortical thinning. Information for all 
modalities and regions is presented in numeric form in Supplemental Tables 1 and 2. 
 
Figure 3: Trajectories of biomarker accumulation in mutation carriers for three cortical 
(top) and three subcortical regions (bottom) for PiB (left), FDG (middle), and structural 
MRI (right) that highlight different patterns of change seen in different brain regions. 
 
Figure 4: Depictions of model estimates of rate of change in PiB (top), FDG (middle), 
and cortical thickness (bottom) in mutation carriers at an EYO of -25, -15, -5, and +5.  
 
Movie 1: Voxel-wise change for beta-amyloid deposition by PiB PET in mutation 
carriers. The top panel of the figure shows the rate of change at each EYO. The bottom 
panel depicts the total biomarker levels at each EYO for mutation carriers derived by 
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integrating the rate of change and adding it to the baseline value of a mutation carrier at 
an EYO of -25 and time zero.  
 
Movie 2: Voxel-wise change in FDG PET uptake in mutation carriers. The top panel of 
the figure shows the rate of change at each EYO. The bottom panel depicts the total 
biomarker levels at each EYO for mutation carriers derived by integrating the rate of 
change and adding it to the baseline value of a mutation carrier at an EYO of -25 and 
time zero. 
 
Movie 3: Voxel-wise change in cortical thickness by MRI in mutation carriers. The top 
panel of the figure shows the rate of change at each EYO. The bottom panel depicts the 
total biomarker levels at each EYO for mutation carriers derived by integrating the rate of 
change and adding it to the baseline value of a mutation carrier at an EYO of -25 and 
time zero. 
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Table 1: Study demographics at baseline.  
 
Demographics at Baseline    
 Non-Carriers Asymptomatic Carriers Symptomatic Carriers 
Number 148 141 88 
Females (%) 85 (57%) 78 (55%) 49 (56%) 
Age (years/sd) 39·5 (11·4) 34·6 (9·2) 45·7 (9·9) 
MMSE (mean/sd) 29·0 (2·7) 28·8 (2·7) 23·9 (10·2) 
CDR-SOB (mean/SD) 0·0 (0·2) 0·0 (0·1) 3·6 (3·5) 
EYO (years/sd) -8·9 (11·4) -13·7 (9·2) 0·5 (7·1) 
PSEN1/PSEN2/APP 122/17/9 
(82/11/6%) 
117/16/8 
(83/11/6%) 
76/6/6 
(86/7/7%) 
N with Follow up (%) 70 (47%) 73 (52%) 58 (66%) 
N of visits*(sd) 2·3 (0·8) 2·3 (0·8) 2·8 (1·2) 
Duration Follow up in years* 
(sd) 3·0 (1·7) 3·0 (1·6) 2·0 (1·3) 
    
Summary of Imaging Data    
Data By Modality PIB FDG MRI 
1 visit 184 177 176 
2 visits 124 131 145 
3 visits 23 27 35 
4 visits 10 11 11 
5 visits 4 5 8 
6 visits 1 1 2 
Total Subjects 346 352 377 
    
*Summary values are only for those individuals with longitudinal data 
EYO - estimated years to dementia onset 
MMSE –Mini Mental State Examination 
CDR-SOB – Clinical Dementia Rating Sum of Boxes  
Formatted: Right
Formatted: Right
Formatted: Right
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Supplemental Text 
 
Statistical Methods 
Longitudinal neuroimaging data is often modeled using repeated measures analysis of variance or cross-
sectional analyses of a summary measurement representing longitudinal trajectories such as annualized 
percent change. Such approaches do not appropriately account for the covariance structure introduced by 
serial measurements and cannot adequately cope with imperfect timing or unbalanced number of data 
points
1
 as is present in the current dataset. Linear mixed-effects (LME) models are a powerful and versatile 
approach to longitudinal analyses of neuroimaging data
2
. The central idea in LME models is to allow a 
subset of regression parameters to vary randomly across subjects. The longitudinal trajectory is modeled as 
a combination of population-level “fixed” effects and subject-specific “random” effects allowing for the 
analysis of between-subject and within-subject sources of variability, which allows subjects to have an 
unequal number of visits or variable intervals between observations. Such models also allow individuals 
with only one time point to contribute to the estimation of all parameters that do not contain longitudinal 
components (e.g. the main effect of baseline EYO). This maximizes the statistical power by utilizing the 
entire available sample. Extensions of the LME framework to neuroimaging data include models that 
account for the spatiotemporal dependencies among neighboring locations
3
. 
 
The general form of our Bayesian multivariate LME model is given by: 
 
                                        
 
where      is a row vector of R regional responses for subject i at time point j within family k.      is a row 
vector of P fixed effects regressors and   is a P by R matrix of fixed effects coefficients. Prior to model 
fitting all data and regressors were standardized to have a mean of 0 and a standard deviation of 1. The 1 by 
R vectors     and    are random intercepts for subject and family respectively. These random intercepts 
accounted for baseline differences in each regional measurement between subjects and families. In order to 
account for intra-individual change, a random slope for time from baseline was included for each subject. 
    is the row vector of R of random slopes for subject i, and      is the time from baseline value for 
subject i at time point j within family k. Finally,   is a R by R covariance matrix. 
 
As with all Bayesian analyses, our model requires the user specify prior distributions for each model 
parameter. We experimented with several different prior distributions, and found our results were 
consistent over a range of priors. Each fixed effect   was assumed to be independently and identically 
distributed with a weak normal prior
4
: 
 
                      
 
The covariance matrix,  , was constructed so that                where    is a vector of R error 
standard deviations with a cauchy prior
4,5
: 
  
                        
 
It is important to understand that while this set of priors assumes that the regional measurement errors are 
independent, our model does not assume that the regional measurements themselves are independent. 
Rather, we use a simplification common to multivariate LME models
6
 and assume that the regional data is 
independent conditional on the subject-level random effects: 
  
                   and                  ) (4) 
 
where    and    are each R by R covariance matrices. Note that while these priors allow for regional 
correlations within intercepts and slopes, they do not allow for correlations between slopes and intercepts. 
While this is unlikely to be true for all biomarker measures, modeling the correlations between all the 
regional slopes and intercepts would require estimating a Rx2 by Rx2 covariance matrix. Without further 
Supplemental Material
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constraints, this would result in a large increase in the number of model parameters. This is something we 
choose to avoid given the relatively small number of time points available for each subject. 
 
The variance and correlation components of    and    were given separate priors in order to eliminate any 
prior relationship between the two components
7,8
. The variance components used Cauchy priors: 
 
                    and                         
 
where   and    are R length vectors of standard deviations for the subject intercept and slope parameters. 
The correlation components used LKJ Cholesky correlation priors
9,4
 
 
                           and                                
 
where    and    are the Cholesky factorizations of the correlation matrices for the intercepts and slopes 
respectively. A value of 1.0 in the LKJ correlation prior implies a uniform prior over all correlation 
matrices
4,10
. Finally, the family level regional intercepts were assumed to be independent, so that:  
 
                           (7) 
 
where    is a vector of R standard deviations: 
 
                    (8) 
 
We tested models where the family intercepts were correlated, but found little evidence for regional 
correlations at this level. 
 
All model fitting was performed using Hamilton Markov chain Monte Carlo implemented in version 2.9.0 
of the probabilistic programming environment Stan
11
. Our Stan model code is included below. Each model 
was run using eight independent chains consisting of 10,000 iterations after 10,000 warm-up samples. In 
order to account for autocorrelation within a chain, we limited analysis to every 10
th
 sample. As a result, all 
inference was performed on 8,000 final samples. Convergence was assessed using the Gelman-Rubin    
statistic
12,13
.    is a ratio of the within chain variance to the pooled between chain variance. At convergence 
this ratio should equal 1.0. In all of our models    was found to be acceptably close to 1.0 for every model 
parameter (Supplemental Figure 1).  
 
 Stan Model, adapted loosely from
14
: 
 
  data { 
    int<lower=1> N;   //Number of data points 
    int<lower=1> nY;               //Number of responses 
    int<lower=1> nB;               //Number of fixed effects 
    vector[nY] y[N];              //Matrix of responses      
    vector[nB] X[N];              //Fixed effects design matrix 
    int<lower=1> nS;               //Number of subjects 
    int<lower=1,upper=nS> subj[N];  //Subject indicator 
    vector[N] Z;              //Subject time from baseline variable 
    int<lower=1> nF;       //Number of families 
    int<lower=1,upper=nF> fam[N]; //Family indicator 
  } 
 
  parameters {  
    matrix[nY,nB] beta;                //Fixed effects coefficients 
    matrix[nY,nS] gammaZ;  //Random normals needed to generate random intercepts for subject 
    matrix[nY,nS] deltaZ;  //Random normals needed to generate random slopes for subject 
    matrix[nY,nF] thetaZ;  //Random normals needed to generate random intercepts for family 
    cholesky_factor_corr[nY] gL;  //Cholesky factorization of the correlation matrix for subject intercepts  
    cholesky_factor_corr[nY] dL;  //Cholesky factorization of the correlation matrix for subject slopes 
    vector<lower=0>[nY] eSigma;  //Error standard deviations 
    vector<lower=0>[nY] gSigma; //Standard deviations for random subject intercepts 
    vector<lower=0>[nY] dSigma; //Standard deviations for random subject slopes 
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    vector<lower=0>[nY] tSigma;  //Standard deviations for family intercepts 
  } 
 
  transformed parameters { 
    matrix[nY,nS] gamma;              //Coefficients for random subject intercepts 
    matrix[nY,nS] delta;          //Coefficients for random subject slopes 
    matrix[nY,nF] theta;          //Coefficients for random family intercepts 
    gamma = diag_pre_multiply(gSigma,gL) * gammaZ;  //Implies gamma ~ Normal(0,Dg) 
    delta = diag_pre_multiply(dSigma,dL) * deltaZ;  //Implies delta ~ Normal(0,Dd) 
    theta = diag_matrix(tSigma) * thetaZ;   //Implies theta ~ Normal(0,Dt) 
  } 
 
  model { 
    vector[nY] mu[N]; 
 
    //Priors 
    gL ~ lkj_corr_cholesky(1.0); 
    dL ~ lkj_corr_cholesky(1.0); 
    to_vector(beta) ~ normal(0,5); 
    to_vector(gammaZ) ~ normal(0,1); 
    to_vector(deltaZ) ~ normal(0,1); 
    to_vector(thetaZ) ~ normal(0,1); 
    eSigma ~ cauchy(0,2.5); 
    gSigma ~ cauchy(0,2.5); 
    dSigma ~ cauchy(0,2.5); 
    tSigma ~ cauchy(0,2.5); 
   
    //Model predictions 
    for (i in 1:N) 
      mu[i] = beta*X[i] + gamma[,subj[i]] + delta[,subj[i]]*Z[i] + theta[,fam[i]]; 
       
    //Likelihood 
    y ~ multi_normal(mu,diag_matrix(eSigma .* eSigma)); 
  } 
 
 
Supplemental Figure 1: Model Convergence measured with   
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Supplemental Figure 1. The Gelman-Rubin    statistic12,13 is a marker that at convergence should equal 1.0. 
In all of our models    was found to be acceptably close to 1.0 for every model parameter.  
Online Interactive Models 
An interactive tool created with the R package Shiny
15
  is hosted online at 
https://dianspatial.shinyapps.io/dian_longitudinal_neuroimaging/. This application provides a more in-
depth depiction of the statistical models and results than is possible in the main manuscript. The online 
application has five distinct tabs: Baseline Trends, Longitudinal Trends (default starting tab), Spatial Maps, 
Regional Comparisons, and Posterior Distributions. For optimal performance, please use a modern version 
of Chrome or Safari. 
 
The Baseline Trends tab takes you to the regional cross-sectional estimates derived as part of the 
longitudinal model. It is possible to view cross-sectional estimates for all three modalities and all brain 
regions. This tab also allows the user to display posterior predictive intervals for a new participant at 
baseline within a new family. The Longitudinal Trends tab depicts the longitudinal model results for all 
modalities and regions in a similar manner to the data presented in Figure 1 of the main manuscript. The 
solid lines in the panel labeled “Fit” are model estimates for each subject. An option is present to display 
the actual data alongside the model fits.  The panel labeled “Estimated Rates” depicts the annualized rate of 
change, with each dot representing an individual’s estimate. The two lines in this panel are group estimates 
of rate of change from the overall model for this selected region. The panel labeled “Estimated Rate 
Differences” depicts differences in the rate of biomarker change between mutation carriers and non-
carriers. For both Baseline Trends and Longitudinal Trends data figures are displayed with baseline EYO -
29 to +10 to avoid inadvertently revealing mutation status at points on the extreme ends of the range where 
sampling is lower. 
 
The Spatial Maps tab provides the ability to display regional model estimates on a rendered brain using the 
rgl package in R
16
. The interactive toolbox allows the user to specify a number of parameters including the 
modality, model parameter of interest, statistic (mean, median, or standard deviation), and color scale. The 
Regional Comparisons tab presents a grid that directly compares the rate of biomarker change between 
anatomical regions (e.g. comparing the rate of PiB accumulation at an EYO of -10 in precuneus and the 
inferior parietal cortex). The values in the matrix always represent a difference between the region listed in 
the row minus the region represented by the column. The Posterior Distributions tab depicts the posterior 
distributions of the model estimates. This distribution provides us with the summary value for a parameter 
as well as the ability to test significance. If the 99% equal-tailed credible intervals do not overlap 0, then we 
consider the model parameter to be significant. 
 5 
Supplementary Table 1: Cortical Regional Timing of Biomarker Abnormality 
Region PiB EYO FDG EYO MRI EYO PiB EYOAdj* FDG EYOAdj* MRI EYOAdj* 
Caudal Anterior 
Cingulate -20·0   -17·2   
Caudal Middle Frontal -19·3 -17·4 -2·8 -16·5 -14·6 0·3 
Cuneus -2·5  -4·7 -0·1  -0·7 
Entorhinal Cortex   -1·8   0·9 
Frontal Pole -18·3   -14·9   
Fusiform Gyrus -17·1  -5·1 -9·8  -1·5 
Inferior Parietal -20·1 -12·4 -10·6 -17·8 -9·2 -7·2 
Inferior Temporal -19·7  -3·5 -16·8  -0·3 
Insula -18·6  -3·1 -15·3  -0·3 
Isthmus Cingulate -20·2  -3·0 -17·8  -0·4 
Lateral Occipital -20·1  -7·2 -17·8  -4·7 
Lateral Orbital Frontal -19·6   -17·0   
Lingual Gyrus -17·9  -8·8 -2·4  -5·6 
Medial Orbital Frontal -21·2  2·3 -19·6  5·1 
Middle Temporal Gyrus -20·5  -5·2 -18·1  -2·7 
Paracentral Gyrus -19·9   -17·5   
Parahippocampus   -9·8   -6·7 
Pars Opercularis -20·7 -13·6 -5·1 -18·3 -8·8 -2·8 
Pars Orbitalis -17·1   -14·8   
Pars Triangularis -19·9  0·0 -17·4  3·0 
Pericalcarine -20·0   -17·6   
Posterior Cingulate -21·0   -18·6   
Postcentral Gyrus -20·6  -2·3 -18·3  1·1 
Precentral Gyrus -18·0  0·0 -14·5  3·1 
Precuneus -22·2 -18·8 -13 -19·8 -16·5 -10·0 
Rostral Anterior 
Cingulate -20·4   -17·6   
Rostral Middle Frontal -20·3   -18·1   
Banks Superior 
Temporal Sulcus -18·7 -18·0 -11·5 -15·8 -15·6 -6·8 
Superior Frontal -19·0 -15·1 0·8 -16·6  3·0 
Superior Parietal -20·2 -14·9 -9·1 -17·8  -5·7 
Superior Temporal -20·1  -5·6 -17·9  -2·6 
Supramarginal Gyrus -20·1 -2·8 -6·9 -17·7 0·7 -3·6 
Temporal Pole -15·1   -1·5   
Transverse Temporal -17·0  -3·0 -13·3  0·2 
* See Adjusting EYO by Known Dementia Onsets section below for explanation of EYOAdj 
 
Supplementary Table 2: Subcortical Regional Timing of Biomarker Abnormality 
Region PiB EYO FDG EYO MRI EYO PiB EYOAdj* FDG EYOAdj* MRI EYOAdj* 
Nucleus Accumbens -22·2  -8·0 -20·8  -3·0 
Amygdala   -0·5   2·8 
Caudate -16·4  3·6 -0·7  5·9 
Hippocampus   -7·1   -3·7 
Pallidum       
Putamen -17·0   -9·4   
Thalamus       
* See Adjusting EYO by Known Dementia Onsets section below for explanation of EYOAdj 
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Regional Comparisons of Biomarker Accumulation  
 
 
 
Supplemental Figure 2: Panel 2A presents regional pair-wise comparisons in rates of beta-amyloid 
deposition at EYOs of -25, -15, -5 and +5. The color-coding on the figures represents the estimated 
differences between regional rates. Only comparisons whose 99% credible intervals do not overlap 0 are 
shown. The comparison is always the region listed in the row minus the region listed in the column. 
Supplemental Figure 2B compares similarly compares subcortical accumulation of beta-amyloid. 
 
 
 
Supplemental Figure 3: Differences in longitudinal rates of FDG changes in A) cortical and B) subcortical 
regions respectively.  
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Supplemental Figure 4: Differences in longitudinal rates of change in A) cortical thickness and B) 
subcortical volume respectively.  
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Movies Illustrating Rates of Change 
To further illustrate patterns of regional change we examined our data at the voxel-wise level. PET data 
were partial volume corrected using a region-bases voxel-wise (RBV)
17
 approach which is a voxel-wise 
extension of the regional spread function technique implemented on our ROI analyses. Data were smoothed 
on the cortical surface using a 10 mm kernel. Our linear mixed-effects models were then fit at a voxel-wise 
level using the R statistical software package lme4
18
 (https://github.com/lme4/lme4). The model estimates 
were then used to compose the movies included with the main body of the manuscript. The upper portion of 
the movie depicts the rate of change of the biomarker (PiB, FDG, MRI) across EYO (from -25 to +10) in 
mutation carriers.  The bottom portion of the movie figure depicts the total biomarker levels at each EYO 
for mutation carriers. This is derived from integrating the rate of change and adding it to the estimated 
value of a mutation carrier at an EYO of -25 and time zero.  
 
Movie 1: Voxel-wise change for beta-amyloid deposition by PiB PET in mutation carriers. The top panel of 
the figure shows the rate of change at each EYO. The bottom panel depicts the total biomarker levels at 
each EYO for mutation carriers derived by integrating the rate of change and adding it to the baseline value 
of a mutation carrier at an EYO of -25 and time zero.  
 
Movie 2: Voxel-wise change in FDG PET uptake in mutation carriers. The top panel of the figure shows the 
rate of change at each EYO. The bottom panel depicts the total biomarker levels at each EYO for mutation 
carriers derived by integrating the rate of change and adding it to the baseline value of a mutation carrier at 
an EYO of -25 and time zero. 
 
Movie 3: Voxel-wise change in cortical thickness by MRI in mutation carriers The top panel of the figure 
shows the rate of change at each EYO. The bottom panel depicts the total biomarker levels at each EYO for 
mutation carriers derived by integrating the rate of change and adding it to the baseline value of a mutation 
carrier at an EYO of -25 and time zero. 
 
Adjusting EYO by Known Dementia Onsets 
Prior analyses examining ADAD have used self-report of parental age of onset
19
 or mutation specific
20
 
estimates of disease onset. To be consistent with prior work in the field, the current analyses utilize these 
two measures to define an individual’s estimated years to symptom onset (EYO). However, the 
longitudinal clinical assessments given as part of DIAN provide the ability to relate expected times of 
dementia onset to the point where clinicians note the first departure from clinical normality. To do this we 
examined those mutation carriers who went from cognitive normality at baseline, denoted by a CDR
21
=0, to 
CDR>0. The first point where an individual reached a CDR>0 was considered their decline age (DA). The 
relationship between the individuals’ DA and parental estimated age of onset (EAO) was calculated using a 
bivariate linear errors-in-variables modeling using the R package “levi”22.   
 
As seen in the Supplemental Figure 5, individuals regularly show a clinical decline (CDR >0) before their 
expected parental EAO. The most likely explanation is that when individuals are reporting the dementia 
onset of a family member they are reporting a cognitive impairment that is more sever than a CDR 0·5. The 
model fit provides a way to adjust calculate a DA in both carriers and non-carriers to capture this early 
clinical decline. This calculated DA can be used to compute an adjusted EYO (EYOadj). All analytical 
models were re-run using this EYOadj. The significant findings using EYOadj are highly similar to EYO 
calculated using the standard mutation or parental EAO. Not surprising given the model fit, the emergence 
of biomarker changes (Supplemental Table 1) happens in closer approximation to an EYOadj of 0 (e.g. 
Precuneus PiB emergence shifting from an EYO -22·2 to EYOadj of -19·8). The spatial patterns and relative 
temporal ordering between modalities are preserved (Supplemental Figure 6).  
 
 
 9 
Supplemental Figure 5: Relating EYO to Decline Age
 
 
Supplemental Figure 5. The relational between estimated age of onset and actual decline age (first visit 
CDR >0) calculated using a bivariate linear errors-in-variables modeling using the R package “levi”22.  The 
blue line represents the model fit while the black dashed line is the identity line.  
 
 
 
Supplemental Figure 6.  
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Supplemental Figure 6: Emergence of neuroimaging biomarkers. The color scale represents the first point 
in the disease using the adjusted EYO (EYOadj) where rates of biomarker change in that cortical region are 
significantly different between mutation carriers and non-carriers. As with the results presented in Figure 2 
in the main text, there is a temporal evolution where increased amyloid deposition precedes 
hypometabolism that in turn is followed by cortical thinning. 
 
 
Dutch and Flemish Mutation Carriers 
Autosomal dominant mutation carriers of the APP Dutch (Glu693Gln) and Flemish (Ala692Gly) mutations 
often present with predominant vascular Aβ deposition, with diffuse plaques in the parenchymal tissue, 
cerebral hemorrhage, and cerebral amyloid angiopathy (CAA).
23
 This Aβ can be problematic for PET 
imaging and these phenotypes may also have additional vascular contributions to the progression of their 
disease.
24
 For these reasons the main analyses excluded all individuals from families of either mutation. We 
additionally ran all models including these two individuals with families with Flemish mutations twenty-
one individuals with the Dutch mutation. Results were highly consistent with those presented in the main 
text.  
  
Dutch Glu693Gln mutation 
http://www.molgen.vib-
ua.be/ADMutations/Default.cfm?MT=1&ML=0&Page=PublicationsByMut&ID=153 
 
Flemish Ala692Gly mutation 
 http://www.molgen.vib-
ua.be/ADMutations/Default.cfm?MT=1&ML=0&Page=PublicationsByMut&ID=56 
  
Obtaining DIAN Data 
Data from the DIAN project can be requested freely by researchers at the following website 
https://dian.wustl.edu/our-research/observational-study/dian-observational-study-investigator-resources/ 
 
 
Movie Legends 
Movie 1: Voxel-wise change for beta-amyloid deposition by PiB PET in mutation carriers. The top panel 
of the figure shows the rate of change at each EYO. The bottom panel depicts the total biomarker levels at 
each EYO for mutation carriers derived by integrating the rate of change and adding it to the baseline value 
of a mutation carrier at an EYO of -25 and time zero.  
 
Movie 2: Voxel-wise change in FDG PET uptake in mutation carriers. The top panel of the figure shows 
the rate of change at each EYO. The bottom panel depicts the total biomarker levels at each EYO for 
mutation carriers derived by integrating the rate of change and adding it to the baseline value of a mutation 
carrier at an EYO of -25 and time zero. 
 
Movie 3: Voxel-wise change in cortical thickness by MRI in mutation carriers. The top panel of the figure 
shows the rate of change at each EYO. The bottom panel depicts the total biomarker levels at each EYO for 
mutation carriers derived by integrating the rate of change and adding it to the baseline value of a mutation 
carrier at an EYO of -25 and time zero. 
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Figure1 Spaghetti Plot For Print
Click here to download Figure: Figure1_spagetti_censor_noDutch_c_for_print.pdf
Figure 2 EYO
Click here to download Figure: Figure2_eyo_noDutch_c_revision.pdf
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Cortical PiB: MC Regional Rate Comparisons
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Subcortical PiB: MC Regional Rate Comparisons
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Cortical FDG: MC Regional Rate Comparisons
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Subcortical FDG: MC Regional Rate Comparisons
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Cortical Thickness: MC Regional Rate Comparisons
Entorhinal
Fusiform
Temporal Pole
Middle Temporal
Inferior Parietal
Precuneus
Caudal Middle Frontal
Parahippocampal
Superior Temporal
Supramarginal
Banksts
Inferior Temporal
Isthmus Cingulate
Superior Parietal
Precentral
Superior Frontal
Lateral Occipital
Frontal Pole
Pars Opercularis
Lingual
Postcentral
Paracentral
Medial Orbitofrontal
Transverse Temporal
Rostral Middle Frontal
Insula
Pars Triangularis
Cuneus
Posterior Cingulate
Pericalcarine
Pars Orbitalis
Rostral Anterior Cingulate
Lateral Orbitofrontal
Caudal Anterior Cingulate
En
to
rh
in
al
Fu
si
fo
rm
Te
m
po
ra
l P
o
le
M
id
dl
e 
Te
m
po
ra
l
In
fe
rio
r P
ar
ie
ta
l
Pr
ec
un
eu
s
Ca
ud
al
 M
id
dl
e 
Fr
o
n
ta
l
Pa
ra
hi
pp
oc
am
pa
l
Su
pe
rio
r T
em
po
ra
l
Su
pr
am
ar
gi
na
l
B
an
ks
ts
In
fe
rio
r T
em
po
ra
l
Is
th
m
u
s 
Ci
ng
ul
at
e
Su
pe
rio
r P
ar
ie
ta
l
Pr
ec
en
tr
al
Su
pe
rio
r F
ro
n
ta
l
La
te
ra
l O
cc
ip
ita
l
Fr
o
n
ta
l P
o
le
Pa
rs
 O
pe
rc
u
la
ris
Li
ng
ua
l
Po
st
ce
nt
ra
l
Pa
ra
ce
n
tr
al
M
ed
ia
l O
rb
ito
fro
n
ta
l
Tr
an
sv
er
se
 T
em
po
ra
l
R
os
tr
al
 M
id
dl
e 
Fr
o
n
ta
l
In
su
la
Pa
rs
 T
ria
ng
ul
ar
is
Cu
ne
us
Po
st
er
io
r C
in
gu
la
te
Pe
ric
al
ca
rin
e
Pa
rs
 O
rb
ita
lis
R
os
tr
al
 A
nt
er
io
r C
in
gu
la
te
La
te
ra
l O
rb
ito
fro
n
ta
l
Ca
ud
al
 A
nt
er
io
r C
in
gu
la
te
Region
R
eg
io
n
EYO =  −25A)
Entorhinal
Fusiform
Temporal Pole
Middle Temporal
Inferior Parietal
Precuneus
Caudal Middle Frontal
Parahippocampal
Superior Temporal
Supramarginal
Banksts
Inferior Temporal
Isthmus Cingulate
Superior Parietal
Precentral
Superior Frontal
Lateral Occipital
Frontal Pole
Pars Opercularis
Lingual
Postcentral
Paracentral
Medial Orbitofrontal
Transverse Temporal
Rostral Middle Frontal
Insula
Pars Triangularis
Cuneus
Posterior Cingulate
Pericalcarine
Pars Orbitalis
Rostral Anterior Cingulate
Lateral Orbitofrontal
Caudal Anterior Cingulate
En
to
rh
in
al
Fu
si
fo
rm
Te
m
po
ra
l P
o
le
M
id
dl
e 
Te
m
po
ra
l
In
fe
rio
r P
ar
ie
ta
l
Pr
ec
un
eu
s
Ca
ud
al
 M
id
dl
e 
Fr
o
n
ta
l
Pa
ra
hi
pp
oc
am
pa
l
Su
pe
rio
r T
em
po
ra
l
Su
pr
am
ar
gi
na
l
B
an
ks
ts
In
fe
rio
r T
em
po
ra
l
Is
th
m
u
s 
Ci
ng
ul
at
e
Su
pe
rio
r P
ar
ie
ta
l
Pr
ec
en
tr
al
Su
pe
rio
r F
ro
n
ta
l
La
te
ra
l O
cc
ip
ita
l
Fr
o
n
ta
l P
o
le
Pa
rs
 O
pe
rc
u
la
ris
Li
ng
ua
l
Po
st
ce
nt
ra
l
Pa
ra
ce
n
tr
al
M
ed
ia
l O
rb
ito
fro
n
ta
l
Tr
an
sv
er
se
 T
em
po
ra
l
R
os
tr
al
 M
id
dl
e 
Fr
o
n
ta
l
In
su
la
Pa
rs
 T
ria
ng
ul
ar
is
Cu
ne
us
Po
st
er
io
r C
in
gu
la
te
Pe
ric
al
ca
rin
e
Pa
rs
 O
rb
ita
lis
R
os
tr
al
 A
nt
er
io
r C
in
gu
la
te
La
te
ra
l O
rb
ito
fro
n
ta
l
Ca
ud
al
 A
nt
er
io
r C
in
gu
la
te
Region
R
eg
io
n
EYO =  −15B)
Entorhinal
Fusiform
Temporal Pole
Middle Temporal
Inferior Parietal
Precuneus
Caudal Middle Frontal
Parahippocampal
Superior Temporal
Supramarginal
Banksts
Inferior Temporal
Isthmus Cingulate
Superior Parietal
Precentral
Superior Frontal
Lateral Occipital
Frontal Pole
Pars Opercularis
Lingual
Postcentral
Paracentral
Medial Orbitofrontal
Transverse Temporal
Rostral Middle Frontal
Insula
Pars Triangularis
Cuneus
Posterior Cingulate
Pericalcarine
Pars Orbitalis
Rostral Anterior Cingulate
Lateral Orbitofrontal
Caudal Anterior Cingulate
En
to
rh
in
al
Fu
si
fo
rm
Te
m
po
ra
l P
o
le
M
id
dl
e 
Te
m
po
ra
l
In
fe
rio
r P
ar
ie
ta
l
Pr
ec
un
eu
s
Ca
ud
al
 M
id
dl
e 
Fr
o
n
ta
l
Pa
ra
hi
pp
oc
am
pa
l
Su
pe
rio
r T
em
po
ra
l
Su
pr
am
ar
gi
na
l
B
an
ks
ts
In
fe
rio
r T
em
po
ra
l
Is
th
m
u
s 
Ci
ng
ul
at
e
Su
pe
rio
r P
ar
ie
ta
l
Pr
ec
en
tr
al
Su
pe
rio
r F
ro
n
ta
l
La
te
ra
l O
cc
ip
ita
l
Fr
o
n
ta
l P
o
le
Pa
rs
 O
pe
rc
u
la
ris
Li
ng
ua
l
Po
st
ce
nt
ra
l
Pa
ra
ce
n
tr
al
M
ed
ia
l O
rb
ito
fro
n
ta
l
Tr
an
sv
er
se
 T
em
po
ra
l
R
os
tr
al
 M
id
dl
e 
Fr
o
n
ta
l
In
su
la
Pa
rs
 T
ria
ng
ul
ar
is
Cu
ne
us
Po
st
er
io
r C
in
gu
la
te
Pe
ric
al
ca
rin
e
Pa
rs
 O
rb
ita
lis
R
os
tr
al
 A
nt
er
io
r C
in
gu
la
te
La
te
ra
l O
rb
ito
fro
n
ta
l
Ca
ud
al
 A
nt
er
io
r C
in
gu
la
te
Region
R
eg
io
n
EYO =  −5C)
Entorhinal
Fusiform
Temporal Pole
Middle Temporal
Inferior Parietal
Precuneus
Caudal Middle Frontal
Parahippocampal
Superior Temporal
Supramarginal
Banksts
Inferior Temporal
Isthmus Cingulate
Superior Parietal
Precentral
Superior Frontal
Lateral Occipital
Frontal Pole
Pars Opercularis
Lingual
Postcentral
Paracentral
Medial Orbitofrontal
Transverse Temporal
Rostral Middle Frontal
Insula
Pars Triangularis
Cuneus
Posterior Cingulate
Pericalcarine
Pars Orbitalis
Rostral Anterior Cingulate
Lateral Orbitofrontal
Caudal Anterior Cingulate
En
to
rh
in
al
Fu
si
fo
rm
Te
m
po
ra
l P
o
le
M
id
dl
e 
Te
m
po
ra
l
In
fe
rio
r P
ar
ie
ta
l
Pr
ec
un
eu
s
Ca
ud
al
 M
id
dl
e 
Fr
o
n
ta
l
Pa
ra
hi
pp
oc
am
pa
l
Su
pe
rio
r T
em
po
ra
l
Su
pr
am
ar
gi
na
l
B
an
ks
ts
In
fe
rio
r T
em
po
ra
l
Is
th
m
u
s 
Ci
ng
ul
at
e
Su
pe
rio
r P
ar
ie
ta
l
Pr
ec
en
tr
al
Su
pe
rio
r F
ro
n
ta
l
La
te
ra
l O
cc
ip
ita
l
Fr
o
n
ta
l P
o
le
Pa
rs
 O
pe
rc
u
la
ris
Li
ng
ua
l
Po
st
ce
nt
ra
l
Pa
ra
ce
n
tr
al
M
ed
ia
l O
rb
ito
fro
n
ta
l
Tr
an
sv
er
se
 T
em
po
ra
l
R
os
tr
al
 M
id
dl
e 
Fr
o
n
ta
l
In
su
la
Pa
rs
 T
ria
ng
ul
ar
is
Cu
ne
us
Po
st
er
io
r C
in
gu
la
te
Pe
ric
al
ca
rin
e
Pa
rs
 O
rb
ita
lis
R
os
tr
al
 A
nt
er
io
r C
in
gu
la
te
La
te
ra
l O
rb
ito
fro
n
ta
l
Ca
ud
al
 A
nt
er
io
r C
in
gu
la
te
Region
R
eg
io
n
EYO =  5D)
−0.07
0.00
0.07
mm / year
Supplemental_4a_thickRatePlot
Click here to download Figure: Supplemental_4a_thickRatePlot_noDutch_c.pdf
Subcortical Volume: MC Regional Rate Comparisons
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 Item 
No. Recommendation 
Page  
No. 
Relevant text from 
manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Title Page Longitudinal study 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found 
Abstract Page  
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 1  
Objectives 3 State specific objectives, including any prespecified hypotheses 1-2 
Our current work compares rates of 
biomarker change in a large population 
of mutation carriers (MC) and non-
carriers (NC) throughout the entire 
brain. In this way we can visualize when 
pathology biomarkers first emerge and 
how they spread throughout the course 
of the disease.  
 
Methods5  
Study design 4 Present key elements of study design early in the paper 2-5 Participants and Statistics 
Section 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, 
follow-up, and data collection 
2 Participant section 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of 
participants 
2 
All participants with genetic, clinical, 
and neuroimaging data that passed 
quality control from the tenth 
semiannual data freeze were included in 
the analyses. 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per 
case 
  
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. 4-5 Statistics Section 
STROBE
 2 
Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group 
2-4 Modality specific data 
paragraphs 
Bias 9 Describe any efforts to address potential sources of bias 4-5 Statistics paragraphs as well as 
in depth material in the 
supplemental material 
Study size 10 Explain how the study size was arrived at 2 
All participants with genetic, clinical, 
and neuroimaging data that passed 
quality control from the tenth 
semiannual data freeze were included in 
the analyses. 
Continued on next page   
 3 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why 
2-5 Participants section and stats 
section 
Statistical 
methods 
12 (a) Describe all statistical methods, including those used to control for confounding 4-5 In depth statistical section and 
supplemental material 
(b) Describe any methods used to examine subgroups and interactions 4-5 Described as part of the linear 
mixed effects model 
(c) Explain how missing data were addressed 4-5 Described as part of the linear 
mixed effects model 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy 
Supplemental In the supplemental material we 
discuss how our statistics are robust 
to different numbers of time points 
and unequal sampling.  
(e) Describe any sensitivity analyses Supplemental 
Material 
 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
2 
All participants with genetic, clinical, and 
neuroimaging data that passed quality 
control from the tenth semiannual data 
freeze were included in the analyses. 
Analyses excluded families with the Dutch 
and Flemish Mutation as these APP 
mutations often present with predominant 
cerebral amyloid angiopathy and diffuse Aβ 
plaques. 
(b) Give reasons for non-participation at each stage 2 We only excluded due to these two 
mutations.  
(c) Consider use of a flow diagram   
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders 
13 Demographics table 
(b) Indicate number of participants with missing data for each variable of interest 13 Demoraphics table 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 13 Demoraphics table 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 13 Demoraphics table 
Case-control study—Report numbers in each exposure category, or summary measures of exposure   
Cross-sectional study—Report numbers of outcome events or summary measures   
 4 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision 
(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were 
included 
Figures, 
online 
interactive 
We provide an online resource to 
look at the actual estimates for 
every parameter for every region 
(b) Report category boundaries when continuous variables were categorized   
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
  
Continued on next page   
 5 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   
Discussion 
Key results 18 Summarise key results with reference to study objectives 8 
AD is not static but possesses dynamism in 
terms of what pathological processes first 
appear, and how such pathology propagates 
throughout the brain. As dementia onset is 
predictable in ADAD, it provides an elegant 
model with which to examine pathological 
staging. Characterizing the spatial and 
temporal spread of pathology provides 
insight to the pathophysiology of the disease, 
informs how neuroimaging could aid optimal 
subject recruitment in clinical trials, and is 
critical to measure the efficacy of 
interventions on longitudinal biomarker 
measurements.  
 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
10 Almost all of page 10 considers 
limitations of the study 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
10 
The discussion takes pains to present work in 
a cautions manner. For example “This means 
results at the edges of the EYO range where 
outliers have disproportional influence must 
be interpreted with care. As the DIAN study 
gains more time points longitudinal estimates 
will be improved further and it may be 
possible to compare the three types of 
mutations.” 
Generalisability 21 Discuss the generalisability (external validity) of the study results 10 
Finally, although ADAD can serve as a 
model for sporadic AD, direct comparisons 
must explore potential differences. 
 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based 
13 
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We acknowledge the financial support of 
Fred Simmons and Olga Mohan, the 
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Barnes-Jewish Hospital Foundation, the 
Charles F. and Joanne Knight Alzheimer’s 
Research Initiative, the Hope Center for 
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Rodger Riney fund. Computations were 
performed using the facilities of the 
Washington University Center for High 
Performance Computing, which were 
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*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
